Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 1;73(1):121–131. doi: 10.1002/art.41466

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Flow diagram according to the Consolidated Standards of Reporting Trials (CONSORT) statement, showing the distribution of patients with recurrent or refractory lupus nephritis (LN) at each stage of the study from the time of informed consent to week 96. Reasons for exclusion of patients at each stage are provided. Samples from the per protocol population were evaluated at weeks 24, 48, and 96. RC = treatment with rituximab and cyclophosphamide but no belimumab infusions; RCB = treatment with rituximab, cyclophosphamide, and glucocorticoids followed by weekly belimumab infusions until week 48; SLE = systemic lupus erythematosus.